NI201000183A - Regímenes de dosificación de antiprogestina. - Google Patents
Regímenes de dosificación de antiprogestina.Info
- Publication number
- NI201000183A NI201000183A NI201000183A NI201000183A NI201000183A NI 201000183 A NI201000183 A NI 201000183A NI 201000183 A NI201000183 A NI 201000183A NI 201000183 A NI201000183 A NI 201000183A NI 201000183 A NI201000183 A NI 201000183A
- Authority
- NI
- Nicaragua
- Prior art keywords
- progesterone
- antagonist
- dosage regimes
- woman
- antiprogestin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Abstract
La invención inmediata se relaciona con métodos para administrar composiciones que incluyen un antagonista del receptor de la progesterona. El antagonista de la progesterona puede ser una antiprogestina pura o un modulador selectivo de los receptores de la progesterona (selective progesterone receptor modulator, SPRM). En una aplicación preferida, el antagonista de la progesterona tiene poca afinidad por el receptor de glucocorticoides. En otra aplicación preferida, la administración del antagonista de la progesterona a una mujer no disminuye en forma sustancial los niveles de estrógeno de la mujer. Más preferentemente, el antagonista de la progesterona es CDB-4124.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4847208P | 2008-04-28 | 2008-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201000183A true NI201000183A (es) | 2012-06-06 |
Family
ID=40751037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201000183A NI201000183A (es) | 2008-04-28 | 2010-10-27 | Regímenes de dosificación de antiprogestina. |
Country Status (24)
Country | Link |
---|---|
US (2) | US8426394B2 (es) |
EP (1) | EP2293797B1 (es) |
JP (1) | JP5791499B2 (es) |
KR (2) | KR20130059442A (es) |
CN (2) | CN102014923A (es) |
AR (1) | AR071516A1 (es) |
AU (1) | AU2009241355B2 (es) |
BR (1) | BRPI0911563A2 (es) |
CA (1) | CA2722753C (es) |
CL (1) | CL2009001010A1 (es) |
DK (1) | DK2293797T3 (es) |
EA (3) | EA032646B1 (es) |
ES (1) | ES2561810T3 (es) |
IL (1) | IL208844A0 (es) |
ME (1) | ME01123B (es) |
MX (1) | MX2010011272A (es) |
MY (1) | MY161059A (es) |
NI (1) | NI201000183A (es) |
NZ (1) | NZ589533A (es) |
SG (1) | SG10201408483QA (es) |
TW (1) | TWI477276B (es) |
UA (1) | UA102849C2 (es) |
WO (1) | WO2009134718A1 (es) |
ZA (1) | ZA201007529B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
HUP0900487A2 (hu) * | 2009-08-05 | 2011-03-28 | Richter Gedeon Nyrt | 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására |
UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
EP2471537A1 (en) * | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
SG10201704858PA (en) * | 2012-05-31 | 2017-07-28 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
EP2914268B1 (en) * | 2012-11-02 | 2018-07-04 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
HU230381B1 (hu) * | 2014-02-17 | 2016-03-29 | Richter Gedeon Nyrt | Ipari eljárás szteroid intermedier előállítására |
KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2377418A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
EP0501523B1 (en) | 1983-11-14 | 1997-04-09 | Columbia Laboratories, Inc. | Bioadhesive compositions |
FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
US5439913A (en) * | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
DE69429823T2 (de) * | 1993-11-16 | 2002-08-22 | Schering Ag | Verwendung von stickstoffoxid-synthase-substrat und/oder -donor oder stickstoffoxidhemmer zur herstellung von medikamenten zur behandlung von störungen der uterinen kontraktilität |
DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
UA37259C2 (uk) * | 1995-02-02 | 2001-05-15 | Шерінг Актієнгезеллшафт | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч |
DE69702450T2 (de) | 1996-05-01 | 2001-03-08 | Us Gov Nat Inst Health | 21-substituierte progesteron derivate als antigestagene |
US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
WO1998008471A1 (en) | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US6172052B1 (en) | 1998-12-04 | 2001-01-09 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
EP2033965A3 (en) * | 2000-03-17 | 2012-09-19 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents |
IN191020B (es) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
KR100464159B1 (ko) | 2000-04-03 | 2005-01-03 | 아스텐존슨 인코포레이티드 | 예비 권축형 연락부 부재 |
DK1328276T3 (da) * | 2000-10-18 | 2006-04-03 | Schering Ag | Anvendelse af antiprogestiner til profylakse og behandling af hormonafhængige sygdomme |
PT1411916E (pt) | 2001-07-09 | 2008-12-10 | Repros Therapeutics Inc | Métodos e materiais para o tratamento de deficiência em testosterona nos homens |
AU2004233997C1 (en) | 2003-04-29 | 2014-01-30 | Massachusetts Institiute Of Technology | Methods and devices for the sustained release of multiple drugs |
EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
CN101080205B (zh) * | 2004-07-09 | 2011-10-12 | 人口委员会股份有限公司 | 含孕酮受体调节剂的缓释组合物 |
GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
DE102005028970A1 (de) * | 2005-06-22 | 2006-12-28 | Siemens Ag | Piezoakter mit gesteigertem Hubvermögen |
DE102005030294A1 (de) * | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
WO2007103510A2 (en) * | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
MX343130B (es) * | 2006-10-24 | 2016-10-26 | Repros Therapeutics Inc | Composiciones y métodos para suprimir la proliferación endometrial. |
CA2674440A1 (en) * | 2007-01-17 | 2008-07-24 | Repros Therapeutics Inc. | Methods for improved stability of steroid derivatives |
EP2144601A4 (en) | 2007-04-05 | 2012-10-10 | Univ Kansas | RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE |
WO2008129396A2 (en) | 2007-04-20 | 2008-10-30 | Preglem S.A. | Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding |
TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
US20130066302A1 (en) | 2009-09-29 | 2013-03-14 | MEDIMETRICS Personalized Drug Delivery B.V. | Intrauterine electronic capsule for administering a substance |
-
2009
- 2009-04-09 TW TW098111780A patent/TWI477276B/zh not_active IP Right Cessation
- 2009-04-27 WO PCT/US2009/041826 patent/WO2009134718A1/en active Application Filing
- 2009-04-27 NZ NZ589533A patent/NZ589533A/en not_active IP Right Cessation
- 2009-04-27 KR KR1020137009925A patent/KR20130059442A/ko active Search and Examination
- 2009-04-27 EA EA201401347A patent/EA032646B1/ru not_active IP Right Cessation
- 2009-04-27 DK DK09739520.6T patent/DK2293797T3/en active
- 2009-04-27 ES ES09739520.6T patent/ES2561810T3/es active Active
- 2009-04-27 US US12/990,203 patent/US8426394B2/en active Active
- 2009-04-27 AU AU2009241355A patent/AU2009241355B2/en not_active Ceased
- 2009-04-27 EA EA201071249A patent/EA201071249A1/ru unknown
- 2009-04-27 EP EP09739520.6A patent/EP2293797B1/en active Active
- 2009-04-27 MX MX2010011272A patent/MX2010011272A/es active IP Right Grant
- 2009-04-27 EA EA201990835A patent/EA201990835A3/ru unknown
- 2009-04-27 ME MEP-2010-182A patent/ME01123B/me unknown
- 2009-04-27 CA CA2722753A patent/CA2722753C/en not_active Expired - Fee Related
- 2009-04-27 SG SG10201408483QA patent/SG10201408483QA/en unknown
- 2009-04-27 UA UAA201014039A patent/UA102849C2/ru unknown
- 2009-04-27 JP JP2011506497A patent/JP5791499B2/ja not_active Expired - Fee Related
- 2009-04-27 MY MYPI2010004777A patent/MY161059A/en unknown
- 2009-04-27 CN CN2009801149788A patent/CN102014923A/zh active Pending
- 2009-04-27 KR KR20107026587A patent/KR20110014162A/ko not_active Application Discontinuation
- 2009-04-27 CN CN201610029200.9A patent/CN105616427A/zh active Pending
- 2009-04-27 BR BRPI0911563A patent/BRPI0911563A2/pt not_active Application Discontinuation
- 2009-04-28 AR ARP090101513 patent/AR071516A1/es unknown
- 2009-04-28 CL CL2009001010A patent/CL2009001010A1/es unknown
-
2010
- 2010-10-20 IL IL208844A patent/IL208844A0/en unknown
- 2010-10-21 ZA ZA2010/07529A patent/ZA201007529B/en unknown
- 2010-10-27 NI NI201000183A patent/NI201000183A/es unknown
-
2013
- 2013-04-02 US US13/855,559 patent/US8735381B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201000183A (es) | Regímenes de dosificación de antiprogestina. | |
AR117670A2 (es) | Modulador del receptor de andrógeno y sus usos | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
CL2009001560A1 (es) | Composición nutricional para bebes que comprende una mezcla de oligosacáridos compuesta de oligosacáridos n-acetilados, galactooligosácaridos y oligosacáridos sialilados; y su uso. | |
CL2011003172A1 (es) | Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos. | |
ECSP077236A (es) | Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos | |
UY31622A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2 | |
EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
CR8847A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y usos de los mismos | |
ECSP10010439A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
GT201700270A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
UY30109A1 (es) | Formas farmacológicas en forma de película para usar en la cavidad bucal (obleas) | |
PE20181523A1 (es) | Tratamiento de lupus nefritis usando laquinimod | |
CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
CR9468A (es) | Oblea que contiene hormonas esteroides | |
TW200738269A (en) | Oral delivery of therapeutic agents using tight junction agonists | |
AR084707A1 (es) | Una composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociados al sistema cardiovascular | |
CL2017002920A1 (es) | Régimen modulador selectivo de los receptores de progesterona (sprm). | |
SV2009003168A (es) | Derivados de oxazolidona como moduladores pr | |
GT200600272A (es) | Moduladores no esteroides de receptores de progesterona | |
CL2011001207A1 (es) | Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos. | |
UY32005A (es) | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a | |
PE20090805A1 (es) | COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL |